Questions About Cancer? 1-800-4-CANCER

Ewing Sarcoma Treatment (PDQ®)

Health Professional Version
Last Modified: 10/18/2013

Changes to This Summary (10/18/2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added text to state that primary sites of bone disease include the hand and foot (3%) (cited Froeb et al. as reference 13).

Added Rowe et al. as reference 15.

Added text about prior treatment for cancer as a pretreatment prognostic factor for Ewing sarcoma (cited Applebaum et al. as reference 28).

Treatment Option Overview

Added Gaspar et al. as reference 33.

Ewing Sarcoma: Recurrent Tumors

Added Fox et al. as reference 11 and level of evidence 3iiA.

Added text to state that a phase I trial of insulin-like growth factor 1 receptor antibodies combined with the mTOR inhibitor temsirolimus achieved two complete responses and three minor responses among 17 patients with metastatic recurrent Ewing sarcoma (cited Naing et al. as reference 23).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.